B-cell repertoire specific for an unfolded self-determinant of mouse lysozyme escape tolerance and dominantly participate in the autoantibody response

Por Tsujihata, Yoshiyuki, Mizukami, Yousuke, Ueda, Tadashi, So, Takanori, Imoto, Taiji
Publicado em 2002

Fasiglifam (TAK‐875) has dual potentiating mechanisms via Gαq‐GPR40/FFAR1 signaling branches on glucose‐dependent insulin secretion

Por Sakuma, Kensuke, Yabuki, Chiori, Maruyama, Minoru, Abiru, Akiko, Komatsu, Hidetoshi, Negoro, Nobuyuki, Tsujihata, Yoshiyuki, Takeuchi, Koji, Habata, Yugo, Mori, Masaaki
Publicado no Pharmacol Res Perspect (2016)

Antihypertrophic Effects of Small Molecules that Maintain Mitochondrial ATP Levels Under Hypoxia

Por Nagai, Hiroaki, Satomi, Tomoko, Abiru, Akiko, Miyamoto, Kazumasa, Nagasawa, Koji, Maruyama, Minoru, Yamamoto, Satoshi, Kikuchi, Kuniko, Fuse, Hiromitsu, Noda, Masakuni, Tsujihata, Yoshiyuki
Publicado no EBioMedicine (2017)

A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1

Por Yabuki, Chiori, Komatsu, Hidetoshi, Tsujihata, Yoshiyuki, Maeda, Risa, Ito, Ryo, Matsuda-Nagasumi, Kae, Sakuma, Kensuke, Miyawaki, Kazumasa, Kikuchi, Naoya, Takeuchi, Koji, Habata, Yugo, Mori, Masaaki
Publicado em 2013

Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist

Por Negoro, Nobuyuki, Sasaki, Shinobu, Mikami, Satoshi, Ito, Masahiro, Suzuki, Masami, Tsujihata, Yoshiyuki, Ito, Ryo, Harada, Ayako, Takeuchi, Koji, Suzuki, Nobuhiro, Miyazaki, Junichi, Santou, Takashi, Odani, Tomoyuki, Kanzaki, Naoyuki, Funami, Miyuki, Tanaka, Toshimasa, Kogame, Akifumi, Matsunaga, Shinichiro, Yasuma, Tsuneo, Momose, Yu
Publicado em 2010